source
- Eli Lilly to acquire non-opioid pain drug developer 4E Therapeutics, adding MNK inhibitor pipelineEli Lilly announced it will purchase 4E Therapeutics, a biotech focused on non‑opioid pain treatments. The acquisition gives Lilly access to 4E’s experimental pipeline, including MNK inhibitors su…
- Edgewise Therapeutics' experimental heart drug meets Phase 2 endpoints in cardiomyopathy trialEdgewise Therapeutics reported that its oral candidate EDG-7500 achieved the predefined goals of a Phase 2 study in both obstructive and non‑obstructive hypertrophic cardiomyopathy. The trial demo…